Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BUV615 Rat Anti-Human CAT1 (SLC7A1)
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      ATRC1; CAT-1; ERR; REC1L; SLC7A1; ecotropic retroviral leukemia receptor homolog
      Human (Tested in Development)
      Rat IgG2b, κ
      Human CAT1 Transfected Cells
      Flow cytometry (Qualified)
      0.2 mg/ml
      6541
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Note:  When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed.  For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      3. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      4. CF™ is a trademark of Biotium, Inc.
      5. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      7. BD Horizon Brilliant Ultraviolet 615 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
      8. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      9. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      10. Researchers should determine the optimal concentration of this reagent for their individual applications.
      11. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      Show More blue down arrow Show Less blue up arrow
      756438 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      CA2

      The CA2 monoclonal antibody specifically recognizes Cationic amino acid transporter-1 (CAT1), which is also known as High affinity cationic amino acid transporter 1 (SLC7A1). CAT1 (SLC7A1) is a ~ 67 kDa ubiquitously expressed glycosylated transmembrane protein encoded by SLC7A1 which belongs to cationic amino acid transporters (CAT) subfamily within the solute carrier (SLC) 7 family. In non-hepatic tissues, this high-affinity, low capacity permease mediates the bidirectional transport of cationic amino acids (arginine, lysine and ornithine) by facilitated diffusion across membranes for cellular metabolism. CAT1 (SLC7A1) provides key support for T cell growth and proliferation and is also known as a potential ecotropic retroviral leukemia receptor. CAT1 (SLC7A1) protein is highly expressed in certain cancers, such as breast, colorectal and chronic lymphocytic leukemia, including inflammatory and autoimmune diseases. This protein reportedly serves as a promising regulator of adaptive immune responses in tumor immunity or inflammation.

      756438 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BUV615
      The BD Horizon Brilliant™ Ultraviolet 615 (BUV615) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 615-nm. BUV615, driven by BD innovation, is designed to be excited by the ultraviolet laser (355 nm) and detected using an optical filter centered near 615-nm (e.g, 610/20 bandpass filter). The acceptor dye can be excited by the Blue (488-nm) and yellow-green (561-nm) lasers resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BUV615
      Ultraviolet 355 nm
      350 nm
      615 nm
      756438 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "756438" on CiteAb

      Development References (8)

      1. Abdelmagid SA, Rickard JA, McDonald WJ, Thomas LN, Too CK. CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines.. J Cell Biochem. 2011; 112(4):1084-92. (Biology). View Reference
      2. Closs EI, Simon A, Vékony N, Rotmann A. Plasma membrane transporters for arginine.. J Nutr. 2004; 134(10 Suppl):2752S-2759S; discussion 2765S-2767S. (Biology). View Reference
      3. Jungnickel KEJ, Parker JL, Newstead S. Structural basis for amino acid transport by the CAT family of SLC7 transporters.. Nat Commun. 2018; 9(1):550. (Biology). View Reference
      4. Lu Y, Hao C, Yu S, et al. Cationic amino acid transporter-1 (CAT-1) promotes fibroblast-like synoviocyte proliferation and cytokine secretion by taking up L-arginine in rheumatoid arthritis.. Arthritis Res Ther. 2022; 24(1):234. (Biology). View Reference
      5. Okita K, Hara Y, Okura H, et al. Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene.. Cancer Sci. 2021; 112(2):563-574. (Immunogen). View Reference
      6. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters.. Pflugers Arch. 2004; 447(5):532-42. (Biology). View Reference
      7. Werner A, Amann E, Schnitzius V, et al. Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation.. Eur J Immunol. 2016; 46(1):92-103. (Biology). View Reference
      8. Werner A, Pieh D, Echchannaoui H, et al. Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability.. Front Oncol. 2019; 9:1268. (Biology: Cytotoxicity, Flow cytometry, Immunohistochemistry, Inhibition). View Reference
      View All (8) View Less
      756438 Rev. 1

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.